Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CAMOMILE-2
NCT06903611Phase 3Not yet recruiting
- Sponsor
- Cambium Bio
- Start
- Oct 2026
- Primary completion
- Nov 2027
- Modality
- Recombinant Proteins and Enzymes, Cell Therapies
01
Overview
Phase 3, randomised, double-blind trial of CAM-101 in dry eye disease (DED) (2 arms), sponsored by Cambium Bio. Primary endpoints: Corneal Fluorescein Staining Score at 9 weeks and Eye Discomfort Score at 9 weeks. Planned start Oct 2026; status: not yet recruiting.
02
Drugs
CAM-101
03
Conditions
dry eye disease (DED)
Beyond the preview
Go deeper on NCT06903611.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06903611.